Search

everythinglearnresearchcommunity

for

Search:↓

User asks about Pyrilutamide for hair loss and its cost. Questions include legitimacy of selleckchem, vehicle to use, and storage.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

The use of PRP to treat hair loss and its potential effectiveness when combined with 5 alpha reductase blockers such as Minoxidil or Finasteride.

The conversation discusses using S5 plus cream (Spironolactone, Alfatradiol, and Tempol) as an alternative to finasteride for hair loss, with concerns about its effectiveness and potential systemic absorption. The original poster already uses 5% minoxidil and is seeking alternatives due to fears of finasteride's side effects.

PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.

Stemson Therapeutics has shut down, disappointing those seeking a hair loss cure. Current treatments like minoxidil, finasteride, and dutasteride are discussed, with some users experiencing side effects and exploring alternatives like PP405.

Microneedling with RU58841 may not be necessary since RU works topically by occupying receptors before DHT binds. RU58841 is a topical anti-androgen.

The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.

RU58841 stopped shedding after two weeks and improved hair after eight months. Initial thinning may occur within the first month.

Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

The user is experiencing hair regrowth after 8 months using 1mg finasteride three times a week, topical minoxidil twice a day, and recently started microneedling with a 1mm needle. Optimal results are expected after one year.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

A user is attempting to recover from severe hair loss using 1.25mg finasteride, 5mg topical minoxidil twice daily, pyrilutamide for a month, RU58841 for two weeks, and weekly microneedling at 1.5mm. They have seen new hair growth after two months and plan to continue the treatment for a year with the hope of regrowing enough hair for a transplant.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.

The clinic diagnosed the user with NW3 and AGA, noting thinning hair despite using finasteride for 3 years, and suggested PRP and Mesotherapy before considering a transplant. The user questions the necessity of these treatments without confirming retrograde alopecia and its treatability.

DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

RU58841 powder storage, with differing opinions on whether to store it in the freezer or at room temperature. One user prefers the freezer, while a company suggests room temperature.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.

Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.

The discussion focuses on hair loss treatments, with suggestions to increase oral Dutasteride to 1 mg or more, as topical Dutasteride is less effective. Other treatments mentioned include RU58841, Minoxidil, and dermastamping, with some users recommending injectable mesotherapy and topical Finasteride.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

A 23 year old male's 9-month progress with 1mg/day of finasteride, which has been life changing and resulted in a significant improvement in hair thickness.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.

The conversation is about users trying to regain access to a Discord server related to pp405 research, with differing opinions on the effectiveness of pp405 for hair loss. Specific treatments like Minoxidil, finasteride, and RU58841 are not mentioned in the conversation.

The user is considering switching from topical finasteride to RU58841 or KX826 due to side effects like low libido and ED. They are also using oral minoxidil and considering low-dose saw palmetto to maintain their hairline.

The user shares their experience with hair loss treatments, including oral finasteride, oral minoxidil, and a topical lotion for dandruff, expressing dissatisfaction with past treatments like PRP and hair transplants. They seek advice on a DNA test to determine suitable medications and express frustration with dermatologists' advice.